Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6097-6105

  Brennan, B J ^a   Wang, K ^a   Blotner, S ^a   Magnusson, M O ^b   Wilkins, J J ^b   Martin, P ^c   Solsky, J ^a   Nieforth, K ^a   Wat, C ^d   Grippo, J F ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b SGS Medisearch International NV   (Belgium)

^c UNIVERSITY OF MIAMI   (United States)

^d ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HEMODIALYSIS; HEPATITIS C; HUMAN; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIMULATION; STEADY STATE; BLOOD; CLINICAL TRIAL; COMPLICATION; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHYSIOLOGY; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RENAL INSUFFICIENCY; RIBAVIRIN; SEVERITY OF ILLNESS INDEX;

EID: 84887489376     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00608-13     Document Type: Article

References (26)

1. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. 2011. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 31:1090- 1101.
2. Lavanchy D. 2009. The global burden of hepatitis C. Liver Int. 29(Suppl 1):74-81.
3. Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE. 2011. The incidence, predictors and management of anaemia and its association with virological response in HCV/HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Aliment. Pharmacol. Ther. 33:1234-1244.
4. Perico N, Cattaneo D, Bikbov B, Remuzzi G. 2009. Hepatitis C infection and chronic renal diseases. Clin. J. Am. Soc. Nephrol. 4:207-220.
5. Ghany MG, Strader DB, Thomas DL, Seeff LB. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335- 1374.
6. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. 2003. Hepatitis C and renal disease: an update. Am. J. Kidney Dis. 42:631-657.
7. Welsch C, Jesudian A, Zeuzem S, Jacobson I. 2012. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut. 61(Suppl 1):i36 -i46.
8. Schaefer EA, Chung RT. 2012. Anti-hepatitis C virus drugs in development. Gastroenterology 142:1340-1350.e1. doi:10.1053/j.gastro.2012.02 .015.
9. Lindahl K, Schvarcz R, Bruchfeld A, Ståhle L. 2004. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J. Viral Hepat. 11:84-87.
10. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. 2008. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am. J. Gastroenterol. 103:1981-1988.
11. Maeda Y, Kiribayashi Y, Moriya T, Maruhashi A, Omoda K, Funakoshi S, Murakami T, Takano M. 2004. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Ther. Drug Monit. 26:9-15.
12. Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, Wright TL, Fried M. 2007. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin. Gastroenterol. Hepatol. 5:124-129.
13. Opravil M, Rodriguez-Torres M, Rockstroh J, Snoeck E, Chung RT, Tietz A, Torriani FJ. 2012. The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV. HIV Clin. Trials 13:33-45.
14. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. 2006. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br. J. Clin. Pharmacol. 62:699-709.
15. Bruchfeld A, Lindahl K, Ståhle L, Söderberg M, Schvarcz R. 2003. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol. Dial. Transplant. 18:1573- 1580.
16. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. 2006. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J. Viral Hepat. 13:316-321.
17. van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW, Tan AC. 2008. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol. Dial. Transplant. 23:721-725.
18. Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. 2006. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br. J. Clin. Pharmacol. 62: 710-714.
19. Anderson B, Holford N. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303- 332.
20. Lertora JJ, Rege AB, Lacour JT, Ferencz N, George WJ, VanDyke RB, Agrawal KC, Hyslop NE, Jr. 1991. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 50:442-449.
21. Morello J, Rodríguez-Novoa S, Jiménez-Nácher I, Soriano V. 2008. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J. Antimicrob. Chemother. 62:1174-1180.
22. Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, Schena FP, DiLeo A, Francavilla A. 2007. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J. Hepatol. 46:768-774.
23. Rowland M, Tozer T. 1995. Clinical pharmacokinetics: concepts and applications, 3rd ed, p 443-462. Lippincott, Williams and Wilkins, Baltimore, MD.
24. Glue P. 1999. The clinical pharmacology of ribavirin. Semin. Liver Dis. 19(Suppl 1):17.
25. Kramer TH, Gaar GG, Ray CG, Minnich L, Copeland JG, Connor JD. 1990. Hemodialysis clearance of intravenously administered ribavirin. Antimicrob. Agents Chemother. 34:489-490.
26. Brennan B, Magnusson M, Wilkins J, Nieforth K, Solsky J, Witt C. 2012. Population pharmacokinetic (PK) analysis of ribavirin (Copegus) in chronic hepatitis C (CHC) patients with chronic kidney disease (CKD) leads to changes in recommended dosingabstr 1093. 47th Annu. Meet. Eur. Assoc. Study Liver, Barcelona, Spain.